Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

armaceuticals, Inc. Consolidated Statements of Operations (unaudited) Three Months Ended Six Months Ended June 30, June 30, ----------------- ----------------- 2009 2008 2009 2008 ---- ---- ---- ---- Revenues: Research grants $324,778 $118,797 $407,790 $605,463 Collaborative research agreements 100,000 50,000 100,000 50,000 ------- ------ ------- ------ Total revenues 424,778 168,797 507,790 655,463 Operating expenses: Research and development 10,528,482 6,220,482 19,327,064 13,125,858 Marketing 475,062 913,916 785,348 1,279,484 General and administrative 1,871,309 1,521,446 3,919,809 3,258,497 --------- --------- --------- --------- Total operating expenses 12,874,853 8,655,844 24,032,221 17,663,839 ---------- --------- ---------- ---------- Loss from operations (12,450,075) (8,487,047) (23,524,431) (17,008,376) Interest income and other, net 88,070 433,750 275,038 1,015,034 ------ ------- ------- --------- Net loss $(12,362,005) $(8,053,297) $(23,249,393) $(15,993,342) ============ =========== ============ ============ Basic and diluted net loss per share $(0.37) $(0.29) $(0.73) $(0.57)
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Regis Technologies looks forward ... for Cancer Research (AACR) annual meeting. Regis will exhibit ... starting Saturday, April 18, in Philadelphia and running through ... title of the oldest and largest organization focused on ... grants, and partners with survivors to promote awareness and ...
(Date:4/16/2015)... April 16, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... Exchange: PBT.U), is pleased to announce that the Company ... April 25, 2015 to be held in ... Bailey and Mr. James Mellon , a ... update on the key programs at its subsidiaries, Portage ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... MENLO PARK, Calif. , April 16, 2015 ... and the Company), a biopharmaceutical company focused on developing ... indications, today announced that the Mayo Clinic Cancer ... site for the ongoing, multicenter Phase I/II study of ... most common and deadly form of human brain cancer. ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... Office for Eastern District of Pennsylvania and U.S. Department ... Settles State Cases with Connecticut and Massachusetts, ... today it has finalized a previously announced agreement in,principle ... of,Pennsylvania, the U.S. Department of Justice and various other ...
... exceptional individuals of all ages who,have reached beyond ... ATLANTA, Sept. 29 UCB today announced ... program, which this year awarded a,total of $300,000 ... The scholarship program was established to recognize individuals,of ...
... Bioscience GmbH,announces that it entered into a ... Icon Genetics group. It provides Nomad access ... expression,technology magnICON(R), for manufacturing biomaterials and selected,biosimilar ... provides,Nomad with a strategically needed freedom to ...
Cached Biology Technology:Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 2Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 3Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 4UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 2UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 3UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 4UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 5
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... were associated with higher levels of high sensitivity C-Reactive protein ... for heart failure patients, in research presented at the American ... high vitamin C intake from food, heart failure patients in ... times more likely to have higher levels of hsCRP, a ...
... kinase, which has been reported in other cancers such ... driver of the rapid metastasis that patients with inflammatory ... of anaplastic lymphoma kinase (ALK) inhibitors may be a ... of breast cancer. These data were presented at ...
... national panel led by Iowa State University engineers ... technologies that capture, use and sequester carbon while ... security. The 33-member National Panel for a ... time in Chicago. Participants represented universities, companies, federal ...
Cached Biology News:Low vitamin C levels may raise heart failure patients' risk 2Signaling pathway linked to inflammatory breast cancer may drive disease metastasis 2Iowa State engineers establish national panel to advance a carbon negative economy 2Iowa State engineers establish national panel to advance a carbon negative economy 3
Mouse monoclonal antibody to UGT2B10 - UDP glucuronosyltransferase 2 family, polypeptide B10...
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
... SM-2 adsorbents are macroporous polystyrene beads for ... surface area for adsorbing organics of molecular ... The beads are useful for the adsorption ... for example, the removal of detergents such ...
Biology Products: